Trials / Completed
CompletedNCT00648323
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxazosin mysylate GITS | Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met. |
Timeline
- Start date
- 2003-11-01
- Completion
- 2005-01-01
- First posted
- 2008-04-01
- Last updated
- 2021-01-29
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00648323. Inclusion in this directory is not an endorsement.